|
|
Volumn 106, Issue 1, 2014, Pages
|
|
Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4-IODO-3-NITROBENZAMIDE;
ANTINEOPLASTIC AGENT;
BENZAMIDE DERIVATIVE;
CARBOPLATIN;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
GEMCITABINE;
INIPARIB;
NEW DRUG;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;
CLINICAL TRIAL (TOPIC);
DRUG ANTAGONISM;
ENZYMOLOGY;
FEMALE;
HUMAN;
LUNG TUMOR;
METHODOLOGY;
MOLECULARLY TARGETED THERAPY;
NOTE;
OVARY TUMOR;
STATISTICAL BIAS;
TREATMENT FAILURE;
TRIPLE NEGATIVE BREAST CANCER;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BENZAMIDES;
BIAS (EPIDEMIOLOGY);
CARBOPLATIN;
CLINICAL TRIALS AS TOPIC;
DEOXYCYTIDINE;
DRUGS, INVESTIGATIONAL;
FEMALE;
HUMANS;
LUNG NEOPLASMS;
MOLECULAR TARGETED THERAPY;
OVARIAN NEOPLASMS;
POLY(ADP-RIBOSE) POLYMERASES;
RESEARCH DESIGN;
TREATMENT FAILURE;
TRIPLE NEGATIVE BREAST NEOPLASMS;
|
|
EID: 84894684013
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djt447 Document Type: Note |
|
Times cited : (29)
|
|
References (0)
|
